Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix
GSK today announced that it has acquired Laboratorios Phoenix, a leading pharmaceutical business, a cash consideration of $253 million.
-
Regulatory update – BLA filed for Benlysta® (belimumab)
GSK announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S.
-
Regulatory update - Benlysta® (belimumab)
GSK announced today that it has submitted a MAA to the EMA, for Benlysta (belimumab) for reducing disease activity in adult patients.
-
GSK announces revised product labels for Serevent and Advair
The changes communicated by the FDA reflect class labeling for all LABA containing products and are specific to product labels in the U.S.
-
European Medicines Agency maintains position on the continued use of Rotarix™ (rotavirus vaccine)
GSK today confirmed that following a meeting of the Committee for Medicinal Products for Human Use (CHMP).
-
Viani (Seretide): German patent litigation update
GSK today confirmed that the Federal Patents Court in Munich, Germany, has ruled in patent litigation regarding GSKs product Viani.
-
New research identifies promising leads to follow in search for medicines to fight malaria
New research conducted by GSK was published in Nature1 identifying promising potential leads to develop new medicines to treat malaria.
-
FDA says Healthcare Providers can resume use of Rotarix (Rotavirus Vaccine, Live, Oral)
GSK announced that the Food and Drug Administration (FDA) has determined that U.S. healthcare practitioners can resume the use of Rotarix.
-
Patrick Vallance appointed to GSK executive leadership team
GSK announced the appointment of Patrick Vallance, Medicines Discovery and Development and as a member of the Corporate Executive Team.
-
GSK extends presence in Asia with new strategic alliance in South Korea
GSK today entered into a strategic alliance with Dong-A, the number one pharmaceutical and OTC Company in South Korea.
-
GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines
GlaxoSmithKline (NYSE: GSK) today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting.
-
GSK announces Q1 results for 2010
GSK delivers Q1 EPS of 30.7p +16% CER before major restructuring
-
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) and today announced topline secondary endpoints from BLISS-76.
-
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab)
GSK and Genmab AS confirmed that EC has granted a conditional marketing authorisation for Arzerra for the treatment of refractory CLL.
-
GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases
GSK has right to license and commercialise compounds at clinical proof-of-concept
-
GSK receives European approval for Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
-
GSK regulatory update – Avodart (dutasteride)
GSK announced today that it has re-submitted sNDA for Avodart (dutasteride) for prostate cancer risk reduction among men.
-
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that the European Medicines Agency (EMA) has maintained its position.
-
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs.
-
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries
Unique finance mechanism ensures vaccinations will begin in 2010 - Up to 300 million doses to be supplied over ten years.
